000860824 001__ 860824
000860824 005__ 20220930130207.0
000860824 0247_ $$2doi$$a10.3389/fonc.2019.00084
000860824 0247_ $$2Handle$$a2128/21649
000860824 0247_ $$2WOS$$aWOS:000458677200001
000860824 0247_ $$2altmetric$$aaltmetric:55573180
000860824 037__ $$aFZJ-2019-01479
000860824 082__ $$a610
000860824 1001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b0
000860824 245__ $$aSuccessful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
000860824 260__ $$aLausanne$$bFrontiers Media$$c2019
000860824 3367_ $$2DRIVER$$aarticle
000860824 3367_ $$2DataCite$$aOutput Types/Journal article
000860824 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550764629_24854
000860824 3367_ $$2BibTeX$$aARTICLE
000860824 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000860824 3367_ $$00$$2EndNote$$aJournal Article
000860824 520__ $$aCurrently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially with BRAF wild-type. However, several checkpoint inhibitor-related complications have been reported, including severe adverse events in the central and peripheral nervous system. In particular, in the recent past, the occurrence of myasthenia gravis following checkpoint inhibitor monotherapy, particularly nivolumab or ipilimumab, has been reported. In contrast, reports on PD-1/CTLA-4 combination blockade—usually with fatal clinical outcome—are scarce. We here report a case with combination immune checkpoint blockade-related myasthenia gravis with favorable clinical outcome.
000860824 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000860824 588__ $$aDataset connected to CrossRef
000860824 7001_ $$0P:(DE-HGF)0$$aSchweinsberg, Viola$$b1
000860824 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b2
000860824 7001_ $$0P:(DE-Juel1)156372$$avon Reutern, Boris$$b3
000860824 7001_ $$0P:(DE-HGF)0$$aMalter, Michael P.$$b4
000860824 7001_ $$0P:(DE-HGF)0$$aSchlaak, Max$$b5
000860824 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b6$$ufzj
000860824 7001_ $$0P:(DE-HGF)0$$aMauch, Cornelia$$b7
000860824 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b8$$eCorresponding author$$ufzj
000860824 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2019.00084$$gVol. 9, p. 84$$p84$$tFrontiers in oncology$$v9$$x2234-943X$$y2019
000860824 8564_ $$uhttps://juser.fz-juelich.de/record/860824/files/2018-0157621-4.pdf
000860824 8564_ $$uhttps://juser.fz-juelich.de/record/860824/files/fonc-09-00084.pdf$$yOpenAccess
000860824 8564_ $$uhttps://juser.fz-juelich.de/record/860824/files/fonc-09-00084.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000860824 8564_ $$uhttps://juser.fz-juelich.de/record/860824/files/2018-0157621-4.pdf?subformat=pdfa$$xpdfa
000860824 8767_ $$82018-0157621-4$$92019-01-29$$d2019-02-21$$eAPC$$jDeposit$$lDeposit: Frontiers$$z743.75 USD, FZJ-2019-01379
000860824 909CO $$ooai:juser.fz-juelich.de:860824$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000860824 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b6$$kFZJ
000860824 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b8$$kFZJ
000860824 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000860824 9141_ $$y2019
000860824 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000860824 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000860824 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2017
000860824 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000860824 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000860824 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000860824 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000860824 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000860824 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000860824 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000860824 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000860824 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000860824 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000860824 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000860824 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000860824 920__ $$lyes
000860824 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000860824 9801_ $$aFullTexts
000860824 980__ $$ajournal
000860824 980__ $$aVDB
000860824 980__ $$aI:(DE-Juel1)INM-3-20090406
000860824 980__ $$aUNRESTRICTED
000860824 980__ $$aAPC